Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel
/Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally
advanced resectable oral squamous cell carcinoma (OSCC), and to determine the safety of
neoadjuvant TTP. In order to explore a better protocol of neoadjuvant therapy to improve the
efficacy in patients with locally advanced OSCC.